ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2520

Psoriatic Arthritis Activity during Pregnancy and the Postpartum� Period

Ari Polachek1, Suzanne Li2, Vinod Chandran1 and Dafna Gladman1, 1Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: pregnancy and psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 10, 2015

Title: Reproductive Issues in Rheumatic Disorders: Basic and Clinical Aspects Poster Session

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Psoriatic arthritis (PsA) often develops between the 3rd -4thdecades of life, including women of childbearing age.  However, little is known about PsA activity during pregnancy and the postpartum period. We aimed to evaluate joint and skin activity of PsA during pregnancy and “postpartum” period.

Methods: Patients with PsA are followed prospectively according to a standard protocol. Data are stored on a computerized database. Women who had pregnancies during follow up between 1990 and 2015 and at least one clinic visit during pregnancy were identified. “Postpartum” period was defined as up to 1 year after pregnancy. PsA activity was defined by 5 states: improvement, worsening (both defined as a change in at least 2 active joints), stable low (defined as 0 or 1 active joint), stable high (defined as ≥ 2 active joints) or a combination of improvement and worsening. Skin activity was defined by 5 states: improvement, worsening (both defined as a change of 1 in the psoriatic area severity index (PASI), stable low (PASI<2), stable high (PASI ≥2) or a combination of improvement and worsening.

Results: 29 PsA women with 42 pregnancies were identified. Of the 42 pregnancies 38 (90%) resulted in live healthy babies, 2 in miscarriages (at the end of the 1sttrimester) and 2 are still pregnant. The mean age at pregnancy was 33.8 ± 4.6. The mean PsA duration was 12 ± 7.4 and the mean psoriasis duration was 19 ± 8.9 years. The mean damaged joint count was 6.3 ± 11.2 and the mean Stienbrocker score was 2 ± 5.5. The majority (24, 58.5%) of pregnancies had either PsA improvement or stable low disease activity, while 13 (31.7%) had either worsening or stable high disease activity (table 1). During the “postpartum” period, 22 (55%) had either improvement or stable low PsA disease activity, while 18 (45%) had either worsening or stable high disease activity. The skin activity during pregnancy had either improved or stayed in a stable low state in 30 (88.3%), worsened in 3 (8.8%) and initially improved with following worsening in 1 pregnancy (table 1). The skin activity during the “postpartum” period had either improved or stayed in stable low in 15 (42.9%) pregnancies, or worsened in 20 (57.1%). During pregnancy, 17 (40.5%) used NSAIDS, 18 (42.9%) used DMARDS, 7 (16.7%) used biologic treatment (6 used anti TNFα agents and 1 Ustekinumab). 

Table 1: Joints and skin activity during pregnancy and “postpartum” period

Time

Favorable course

Unfavorable course

Mixed course

Activity in joints

Improved    Stable low   Total

Worse        Stable high   Total

Improved-worse

Pregnancy, number (%)

11 (26.8)      13 (31.7)      24 (58.5)   

8 (19.5)        5 (12.2)        13 (31.7)      

4 (9.8)

“Postpartum”, number (%)

9 (22.5)        13 (32.5)      22 (55)

17 (42.5)      1 (2.5)          18 (45)

0

Skin activity

 

 

 

Pregnancy, number (%)

14 (41.2)      16 (47.1)      29 (88.3)   

3 (8.8)           0                  3 (8.8)      

1 (2.9)

“Postpartum”, number (%)

3 (8.6)          12 (34.3)      15 (42.9)

20 (57.1)        0                 20 (57.1)

0

Conclusion: The outcome of pregnancy among patients with PsA is excellent. Disease activity in both skin and joints is variable with the majority (60%) improving during pregnancy but worsening in the “postpartum” period.


Disclosure: A. Polachek, None; S. Li, None; V. Chandran, None; D. Gladman, None.

To cite this abstract in AMA style:

Polachek A, Li S, Chandran V, Gladman D. Psoriatic Arthritis Activity during Pregnancy and the Postpartum� Period [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/psoriatic-arthritis-activity-during-pregnancy-and-the-postpartum%ef%bf%bd-period/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/psoriatic-arthritis-activity-during-pregnancy-and-the-postpartum%ef%bf%bd-period/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology